NASDAQ:CLLS - Cellectis Stock Price, Price Target & More

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis (NASDAQ:CLLS) posted its earnings results on Monday, March, 12th. The biotechnology company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.12. The biotechnology company had revenue of $6.91 million for the quarter, compared to analysts' expectations of $10.10 million. Cellectis had a negative return on equity of 35.63% and a negative net margin of 298.01%. View Cellectis' Earnings History.

Cellectis is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Cellectis.

6 equities research analysts have issued 1-year price objectives for Cellectis' stock. Their predictions range from $20.00 to $73.00. On average, they expect Cellectis' stock price to reach $44.00 in the next year. View Analyst Ratings for Cellectis.

Some companies that are related to Cellectis include Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Repligen (RGEN), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Iovance Biotherapeutics (IOVA), REGENXBIO (RGNX), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), La Jolla Pharmaceutical (LJPC), Coherus BioSciences (CHRS) and Novavax (NVAX).

(CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Press coverage about CLLS stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cellectis earned a media sentiment score of 0.03 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.07 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CLLS stock can currently be purchased for approximately $29.71.

Cellectis has a market capitalization of $1.24 billion and generates $33.72 million in revenue each year. The biotechnology company earns $-99,360,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Cellectis employs 122 workers across the globe.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS LLE-DE-FRANCE I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]